Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Cns Pharmaceuticals Inc (NQ: CNSP )

0.2900 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, May 19, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 0.2900
Bid (Size) 0.2715 (597)
Ask (Size) 0.3058 (40)
Prev. Close 0.2900
Today's Range 0.2900 - 0.2900
52wk Range 0.2453 - 2.680
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Lantern Pharma to Host Glioblastoma Multiforme Webinar to Mark Brain Tumor Awareness Month
Via Investor Brand Network
Topics Artificial Intelligence
Exposures Artificial Intelligence
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Abstract to be Presented at American Society of Clinical Oncology 2022 Annual Meeting
Via Investor Brand Network

Performance

YTD
-62.44%
-62.44%
1 Month
-18.49%
-18.49%
3 Month
-12.49%
-12.49%
6 Month
-75.00%
-75.00%
1 Year
-84.41%
-84.41%

More News

Read More
Updated Guidelines Shed Light on Using Radiation Against Brain Metastases
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Announces Q1 2022 Financial, Corporate Update
Via Investor Brand Network
Exposures Product Safety
CNS Pharmaceuticals: Q1 Earnings Insights
Via Benzinga
Researchers Develop Models to Better Understand Brain Cancer Metastasis
Via Investor Brand Network
Investor Event Turns Spotlight on Novel Brain Cancer Drug Candidate Global Trial Under Way by CNS Pharmaceuticals, Inc. (NASDAQ: CNSP)
Via Investor Brand Network
Study Finds Strong Link Between Hormone Drug, Growth of Brain Tumors
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc.’s (NASDAQ: CNSP) Berubicin Demonstrating ‘Encouraging Promise in Treatment of GBM’
Via Investor Brand Network
27 Stocks Moving in Wednesday's Pre-Market Session
Via Benzinga
Johns Hopkins Researchers Receive Millions for New Cancer Research Projects
Via Investor Brand Network
Researchers May Have Found New Way to Slow Progression of Cancer
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Secures Approval from Ethics Committee and Competent Authority in Spain for Potentially Pivotal Study
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's After-Market Session
Via Benzinga
CNS Pharmaceuticals (NASDAQ: CNSP) Focused On Advancing Research On GBM Treatments
Via Benzinga
Plants Could Unlock Future Cancer Therapies
Via Investor Brand Network
12 Health Care Stocks Moving In Friday's After-Market Session
Via Benzinga
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) Focused on Advancing Research on Treatments for GBM, Other Cancers
Via Investor Brand Network
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Via InvestorPlace
JTC Team Announces Continuation of its Virtual Investor Spotlight Series with NASDAQ: AEZS, NASDAQ: CNSP, and NASDAQ: AREC
From JTC Team, LLC
Via AccessWire
European Regulatory Approvals Help CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Advance ‘Potentially Pivotal’ Study of Novel Brain Cancer Drug
Via Investor Brand Network
CNS Pharmaceuticals (NASDAQ: CNSP) To Participate In Upcoming Virtual Investor Event
Via Benzinga
CNS Pharmaceuticals (NASDAQ: CNSP) to Participate in Upcoming Virtual Investor Event
Via Investor Brand Network
BioMedNewsBreaks – CNS Pharmaceuticals Inc. (NASDAQ: CNSP) to Participate in Upcoming Virtual Investor Event
Via Investor Brand Network
CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) Leading the Charge toward Advancing Research on Treatments for Primary and Metastatic Central Nervous System Cancers
Via Investor Brand Network
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.